Deutsche Bank
SABS icon

Deutsche Bank’s SAB Biotherapeutics SABS Stock Holding History

Deutsche Bank’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Buy
+42,371
New +$158K ﹤0.01% 3334

Other funds holding SABS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Deutsche Bank's SABS Position: Q2 2026 in Review

Deutsche Bank opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 42,371 shares worth $165K. The stake represents ﹤0.01% of the portfolio and ranks #3334 among its holdings.

22 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Deutsche Bank held 42,371 shares of SAB Biotherapeutics worth $165K as of Q2 2026.
  • SAB Biotherapeutics was a new Deutsche Bank position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3334 holding.
  • 22 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.